-

Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:

Theraclion (Paris:ALTHE):

Listing venue: Euronext Growth Paris
PEA-PME eligible
ISIN Code: FR0010120402
Website: www.theraclion.com

Under the liquidity contract entrusted by THERACLION to CRÉDIT INDUSTRIEL ET COMMERCIAL, as of June 30, 2026, the following resources were held in the liquidity account:

  • 26,499 shares
  • €3,355.99

During the 1st half of 2026, a total of the following was traded:

BUY

380,553 shares

€234,517.84

1,030 transactions

SELL

368,894 shares

€225,977.25

955 transactions

It is recalled that at the time of signing the contract, the following resources were held in the liquidity account:

  • 31,850 shares
  • €27,935.01

About Theraclion

Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.
High-Intensity Focused Ultrasound (HIFU) requires no incisions or operating room, leaves no scars and allows patients to immediately resume their daily activities. The HIFU method concentrates therapeutic ultrasound toward an internal focal point from outside the body.
Theraclion is developing Sonovein®, a HIFU robotic platform for the treatment of varicose veins, CE-marked under MDR (EU 2017/745), with the potential to replace millions of surgical procedures each year. To date, Sonovein® has been adopted by more than a dozen centres worldwide and has been used in more than 4,000 procedures. In the United States, Sonovein® is not yet available for sale.

Based in Malakoff (Paris), the Theraclion team consists of approximately 40 people.

For more information, please visit www.theraclion.com and follow us on LinkedIn.

Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Ticker: ALTHE - ISIN Code: FR0010120402
LEI : 9695007X7HA7A1GCYD29

Contacts

Theraclion Contact
Martin Deterre
Chief Executive Officer
contact@theraclion.com

Theraclion

BOURSE:ALTHE
Release Versions
EnglishFrench

Contacts

Theraclion Contact
Martin Deterre
Chief Executive Officer
contact@theraclion.com

More News From Theraclion

Theraclion Strengthens Its Governance by Appointing Vincent Gardès as Chairman of Its Board of Directors

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that its Board of Directors, which met on July 8, 2026, has appointed Mr. Vincent Gardès as Chairman of the Board of Directors, with immediate effect. A Director of Theraclion since the General Meeting of June 18, 2026, after having served...

Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: Theraclion (Paris:ALTHE): Listed on Euronext Growth Paris PEA PME eligible ISIN Code: FR0010120402 Website: www.theraclion.com Voting rights: Date Total number of shares of Theraclion Total number of theoretical voting rights of Theraclion (1) Total number of real voting rights of Theraclion (2) 30/06/2026 73 123 311 89 137 355 87 570 061 (1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attache...

Theraclion Announces the Evolution of Its Board of Directors

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that Mr. Yann Duchesne has decided not to stand for re-election as Director and Chairman of the Board following the General Meeting held on June 18, 2026, positions he had held since January 24, 2022. The Company, all members of the Board o...
Back to Newsroom